ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=: =@ 8X@"1Calibri1Arial1Arial1Arial1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_) #,##0\(#,##0_);[RED]\(#,##0\)!"($"#,##0_);[RED]"($"#,##0\)'""($"#,##0.00_);[RED]"($"#,##0.00\) #,##0.00                + ) , *   (  (8  $  $  (  $  $  $ "8  $ (8 ` 8condensed balance sheets"Kcondensed statements of op"acondensed statements of st"condensed statements of ca"Ynotes to condensed financi$5notes to condensed financi-1 4 property and equipment"5 accrued expenses and oth!ymarch 2019 loan agreement"revenue from contracts wit$notes to condensed financi-2Aleasesustockbased compensation"comparison of the three mo"iresearch and development e$research and development e-1"wcomparison of the nine mon$research and development e-2$)research and development e-3"$liquidity and capital reso)item 6 exhibits8item 6 exhibits-1$[Qphasebio pharmaceuticals inc&Tphasebio pharmaceuticals inc-1Wform of terms agreement"9`as adopted pursuant to sec$ cas adopted pursuant to sec-1"esection 906 of the sarbane$hsection 906 of the sarbane-1T:2t     3  @@   NCONDENSED BALANCE SHEETSSeptember 30, 2021December 31, 2020AssetsCurrent assets:Cash and cash equivalents!Prepaid expenses and other assetsTotal current assetsProperty and equipment, net#Operating lease right-of-use assets Other assets Total assets%Liabilities and stockholders' deficitCurrent liabilities:!Current portion of long-term debt.Current portion of deferred sublicense revenue Accounts payable.Accrued expenses and other current liabilitiesTotal current liabilitiesLong-term debt, net Operating lease liabilities, net Deferred sublicense revenue, net Development derivative liabilityOther long-term liabilitiesTotal liabilities(Commitments and contingencies ( Note 9 )Stockholders deficit:Preferred stock, $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding at September 30, 2021 and December 31, 2020Common stock, $0.001 par value; 200,000,000 shares authorized; 48,092,450 shares issued and 48,062,483 shares outstanding at September 30, 2021; 29,471,854 shares issued and 29,441,887 shares outstanding at December 31, 2020UTreasury stock, at cost, 29,967 shares as of September 30, 2021 and December 31, 2020Additional paid-in capitalAccumulated deficitTotal stockholders deficit+Total liabilities and stockholders' deficit"CONDENSED STATEMENTS OF OPERATIONS Three Months Ended September 30,Nine Months Ended September 30,20212020RevenueSublicense revenue$ Grant revenue Total revenueOperating expenses:Research and developmentGeneral and administrativeTotal operating expensesLoss from operationsOther expense:;Loss from remeasurement of development derivative liabilityInterest incomeInterest expenseForeign exchange gain (loss)Total other expenseNet loss before income taxesProvision for income taxesNet loss,Net loss per common share, basic and diluted=Weighted average common shares outstanding, basic and diluted5CONDENSED STATEMENTS OF STOCKHOLDERS EQUITY (DEFICIT) Common StockTreasury StockAdditional Paid-in CapitalAccumulated Deficit(Total Stockholders' Equity (Deficit)SharesAmountBalance at December 31, 20200Issuance of common stock in public offering, netExercises of stock optionsStock-based compensationBalance at March 31, 2021Stock offering costs;Issuance of common stock under employee stock purchase planBalance at June 30, 2021Balance at September 30, 2021Balance at December 31, 2019!Issuance of common stock warrantsExercise of stock optionsBalance at March 31, 2020Balance at June 30, 2020Balance at September 30, 2020"CONDENSED STATEMENTS OF CASH FLOWSOperating activitiesKAdjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortizationNon-cash interest expense)Non-cash research and development expenseOther non-cash transactions,Changes in operating assets and liabilities:Other receivablesDeferred sublicense revenue%Net cash used in operating activitiesInvesting activities#Purchases of property and equipment+Acquisition of intellectual property rights%Net cash used in investing activitiesFinancing activities.Proceeds from development derivative liability>Proceeds from issuance of common stock in public offering, net)Payments of deferred stock offering costs'Proceeds from exercise of stock options=Issuance of common stock through employee stock purchase planRepayments of long-term debt)Net cash provided by financing activities4Net increase (decrease) in cash and cash equivalents8Cash and cash equivalents at the beginning of the period2Cash and cash equivalents at the end of the period%Supplemental disclosure for cash flowCash paid for interestFSupplemental disclosure of non-cash investing and financing activitiesIIssuance of warrants in conjunction with development derivative liabilityZInitial recognition of operating lease right-of-use assets and operating lease liabilitiesQPurchases of property and equipment by incurring development derivative liabilityUPurchases of property and equipment included in accounts payable and accrued expenses'Notes to Condensed Financial StatementsAs of September 30,Common stock options!Warrants to purchase common stockEmployee stock purchase planTotal)Fair Value Measurements at Reporting DateLevel 1Level 2Level 3As of September 30, 2021:Cash equivalents Liabilities)Development derivative liability (Note 8)As of December 31, 2020:4. Property and EquipmentAs of September 30, 2021As of December 31, 2020 Lab equipment)Computer hardware, software and telephoneFurniture and fixturesLeasehold improvementsConstruction in progressLess accumulated depreciation55. Accrued Expenses and Other Current Liabilities"Accrued clinical and related costs&Accrued compensation and related costsAccrued interest,Current portion of operating lease liability Accrued othercMarch 2019 Loan Agreement with Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P.Years Ending December 31,2021 (remaining three months)20222023 ThereafterTotal principal paymentsLess unamortized loan feesTotal term loan borrowings%Revenue from Contracts with CustomersTransaction Price(Cumulative Sublicense Revenue RecognizedDeferred Sublicense RevenueLicense#Development and Regulatory ServicesSupply of License Product=Less current portion of long-term deferred sublicense revenue+Total long-term deferred sublicense revenue Development Derivative LiabilityFunding during the periodChange in fair valueLeasesYear Ending December 31,20242025#Total future minimum lease paymentsLess: Present value adjustmentOperating lease liabilitiesStock-Based Compensation"Three Months Ended September 30,!Nine Months Ended September 30,Total stock-based compensation@Comparison of the Three Months Ended September 30, 2021 and 2020Change Research and Development Expense$Preclinical and clinical development!Compensation and related benefitsFacilities expenseOther'Total research and development expenses5External research and development expense by program: Bentracimab Pemziviptadil-Unallocated research and development expense:)Compensation and stock-based compensationOther research and development?Comparison of the Nine Months Ended September 30, 2021 and 2020Foreign exchange gainLiquidity and Capital ResourcesItem 6. ExhibitsIncorporated by ReferenceExhibit Number Exhibit TitleFormFile No.Exhibit Filing DateSAmended and Restated Certificate of Incorporation of PhaseBio Pharmaceuticals, Inc.8-K 001-38697October 22, 2018=Amended and Restated Bylaws of PhaseBio Pharmaceuticals, Inc.S-1/A 333-227474October 5, 2018Form of Warrant to Purchase Shares of Series B Redeemable Convertible Preferred Stock, issued by PhaseBio Pharmaceuticals, Inc. on December 22, 2009.S-1September 21, 2018Warrant to Purchase Shares of Series C-1 Redeemable Convertible Preferred Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on October 18, 2017.Fourth Amended and Restated Investor Rights Agreement, by and among PhaseBio Pharmaceuticals, Inc. and certain of its stockholders, dated August 27, 2018.~Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on March 25, 2019.10-KMarch 26, 2019Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on March 25, 2019.Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on July 26, 2019.10-QAugust 14, 2019}Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on July 26, 2019.< Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to Silicon Valley Bank on October 2, 2019.November 14, 2019Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to WestRiver Innovation Lending Fund VIII, L.P. on October 2, 2019.Warrant to Purchase Shares of Common Stock, issued by PhaseBio Pharmaceuticals, Inc. to SFJ Pharmaceuticals X, Ltd. on January 9, 2020March 30, 2020:Description of PhaseBio Pharmaceuticals, Inc. Common Stock5.1#Opinion of Cooley LLP10.1#+'2018 Equity Incentive Plan (as amended)10.2#Equity Distribution Agreement, dated November 10, 2021 by and between PhaseBio Pharmaceuticals, Inc. and William Blair & Company, L.L.C.23.1#6Consent of Cooley LLP (included in Exhibit 5.1 hereto)31.1#Certification of Chief Executive Officer and President (Principal Executive Officer), pursuant to Section302 of the Sarbanes-Oxley Act of 2002.31.2#Certification of Chief Financial Officer (Principal Financial Officer), pursuant to Section302 of the Sarbanes-Oxley Act of 2002.Phasebio Pharmaceuticals INCPhaseBio Pharmaceuticals, Inc.By:Name:Title:William Blair & Company, L.L.C.Form of Terms AgreementTitle of Purchased Shares:(Common Stock, par value $0.001 per share%Number of Shares of Purchased Shares:Price to Public:2Purchase Price by William Blair & Company, L.L.C.:<Method of and Specified Funds for Payment of Purchase Price:NBy wire transfer to a bank account specified by the Company in same day funds.Method of Delivery:Free delivery of the Shares to the Manager s account at The Depository Trust Company in return for payment of the purchase price.Time of Delivery:Closing Location:Documents to be Delivered:;The following documents referred to in the Equity Distribution Agreement shall be delivered as a condition to the closing at the Time of Delivery: (1) The opinion or Reliance Letter, as applicable, referred to in Section 4(l). (2) The opinion referred to in Section 4(m). (3) The opinion or Reliance Letter, as applicable, referred to in Section 4(n). (4) The accountants letter referred to in Section 4(o). (5) The officers certificate referred to in Section 4(k). (6) Such other documents as the Manager shall reasonably request.DAS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002November 10, 2021/s/ Jonathan P. Mow)Jonathan P. Mow Chief Executive Officer/s/ John P. Sharp'John P. Sharp Chief Financial Officer-SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Gcc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} $ , @ , , , , , , , , , , , , , , , , , , , , , , , , , , ,           ~ p ~  j   ~ Ҋ ~     ~ f  ~ Vs   ~ f  ~    ~   ~    ~   ~    ~ v  ~        ~ ^T ~  S   ~       ~ & ~  j9   ~ _ ~  \   ~ FO ~     ~ z* ~  i   ~ z ~  2   ~ {      ~ V ~  (   ~   ~     ~  ~              ~  ~  v   ~  ~    ,! ," ,# ,  ~ n5  ~ _  ! !~ !ҷ! !~ ! 6!  "! "~ "" "~ " :v"  #" #~ #v# #~ # #                                           !!!!!!!! """""""" ######## PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,,,,,,,,,,,, #  $ % &  '  & '  (4 ) ~ >   *   ~ Ʀ  * +          ~  , ~ >     ~ Ʀ  ~   -4  . ~   ~ "  ~   ~   / ~ <  ~ 0  ~   ~   0 ~   ~ 2@  ~ >  ~   1 ~ A ~  ҿ   ~ g ~  h 24 3 ~  ~  >   ~ v^ ~ 6| 4 ~  ~     ~ . ~  5 ~  ~  Z   ~  ~  6 ~  ~     ~  ~  7 ~  ~  V   ~ R ~ n 8 ~ 2  ~  &w   ~  ~  9        ~    : ~ 2  ~  &w   ~  ~  ; ~  ~     (\ ~ S < ~ t  ~     ~ !  ~ ub                                                                     PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} '*,* @*,),),), ), ), ), ), ),),),),),),),),),*,),),),),),),),),), =  > ? @ !A"& 'B ()  C D C D) E ~  ~  v   ~ + ~  ~ _  ~ !6" $&~ ':v( F ~  c ~  N       ~   !" $&~ 'Ҫ( G ~            ~ f  !" $&~ 'f( H             ~ z    ! " $&~ 'z  ( :                 ~ !T " $&~ 'T ( I ~ –p   ~   ~ +  ~   ~ R   ~ !j " $&~ 'n ( J             ~ v   ! " $&~ 'v ( G ~ ~8           ~    ! " $&~ ' ( K ~ f          ~ *  !" $&~ '*( H            ~ b   !" $&~ 'b ( :               ~ !?" $&~ '?( L ~ 5u  ~     ~ + ~  ~ f)  ~ !" $&~ 'f( G ~           ~   !" $&~ '( H            ~ B   !" $&~ 'B ( :               ~ !2 " $&~ '2 ( M ~ Tw  ~     ~ + ~  ~ n5  ~ !ҷ" $&~ '(Z) N ~ N ~  v   ~ + ~  ~ Ύ   ~ !J" $&~ '*( O            ~ {  !" $&~ '{( P ~ r          ~ F  !" $&~ 'F( H            ~ ^  !" $&~ '^( :               ~ !" $&~ '( Q ~ u ~  v   ~ + ~  ~ B  ~ !f1" $&~ 'C( F ~ .          ~ f  !" $&~ 'f( G ~ R          ~   !" $&~ '( H            ~   !" $&~ '( ),!),"),#),$),%),&), :                 ~ !JH " $&~ 'JH ( !R !~ !:f! !~ ! v!  ! ~ !+! !~ !! !~ !"! ! ~ !!y!" !$&~ !'f!( "F "~ "`" " " "  "  "" " "" "~ "&" " "!"" "$&~ "'&"( #G #~ ## # # #  #  ## # ## #~ #b# # #!#" #$&~ #'b#( $H $ $$ $ $ $  $  $$ $ $$ $~ $ $ $ $!$" $$&~ $' $( %: % %% % % %  %  %% % %% % %% % ~ %!&w%" %$&~ %'&w%( &S &~ && &~ & v&  & ~ &+& &~ && &~ &S& & ~ &!&" &$&~ &'D&("   !#$&') !#$&')   !"$&'(   !"$&'(   !"$&'(           !" $& '(           !" $& '(           !" $& '(           !" $& '(           !" $& '(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !#$&')   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(   !"$&'(           !" $& '(!!!!!!!! !! !!!!!!!!!!!! !!!"!!$&!!'("""""""" "" """""""""""" ""!"""$&""'(######## ## ############ ##!"##$&##'($$$$$$$$ $$ $$$$$$$$$$$$ $$!"$$$&$$'(%%%%%%%% %% %%%%%%%%%%%% %%!"%%$&%%'(&&&&&&&& && &&&&&&&&&&&& &&!"&&$&&&'(PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , T  % &  '   U : ~  ~    V W ~   ~   H ~ !  ~   3 ~   ~ ΃  X ~   ~   Y ~   ~ r  Z   ~    [ \   ~  F   ~ W ~  J   ~ M ~     ~ z ~    ] ~      ^ ~ S ~  r  _ ` ~  ~  ^  a   ~  r  b ~  ~    c d   ~    e ~ ® ~  -  f ~ b ~  "  g ~ F ~    h ~ *     ,! ," ,# ,$ ,% ,& ,' ,( ,) ,* ,+ , i ~   ~   !j !~ !u! !~ ! !  "k "~ "." "~ " B"  #l #~ #j# #~ # #  $m $~ $p$ $~ $ f$  %n% &o &~ && &~ &  &  'p' (q ( (*( (~ ( {(  )r ) )*) )~ )  )  *s *~ *A* *~ * 0*  +t + +*+ +~ +  +                                          !!!!!!!! """""""" ######## $$$$$$$$ %%%%%%%% &&&&&&&& '''''''' (((((((( )))))))) ******** ++++++++ PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , , , , , , u  v &  '   w ~ N  ~  z  x ~ nh ~  nh  y ~ ~ ~    z ~ 6  ~ +         PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,, u  z  {"    |  } ~  4 4  ~ l ~  l    *  * 4   ~ V   *   *  ~ V  4  4   ~   ~    *   *  4  ~ (   *    * ~ ([                                                PH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @ , , , , , , , ,         ~ N ~     ~ R ~  2   ~ v ~     ~  ~     ~ z   ~ J  ~ *  ~    ~ >  ~    ~ f  ~  *%                 PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @ , , , , , ,         ~ "3 ~  +   ~  ~  R#   ~  ~     ~  ~  .   ~   ~    ~ _  ~ \            PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , ,    ~ R  ~ >U  ~ N     ~    ~    ~ ~       PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , ,          ~  ~      *  ~ ^) ~      ~ V"  ~ jo      ~ jo ~ 8 ~  Ʀ   ~  " ~   " ~ { Z+                    PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, u    E ~ (  ~   ~  M ~ VZ PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,    ~ >  ~   ~   ~ ^  ~ n   ~ ^   ~    ~ v   ~            PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @,,,,     &  '  & '  / ~  ~     ~ " ~ 2 . ~  ~     ~   ~   ~ B  ~      ~ ! ~ "$          PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,,,,,,,   $   &  '  (( ) ~ >   *   ~ > , ~ >      ~ > -(  . ~   ~ "  ~ w  / ~ <  ~ 0  ~    0 ~   ~ 2@  ~   1 ~ A  ~ ҿ  ~   2( 3 ~  ~  >   ~  4 ~  ~     ~  5 ~  ~  Z   ~ 2 6 ~  ~     ~ f 7 ~  ~  V   ~ ^ : ~ 2  ~  &w   ~ c                                                 PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , ,   $   &  '   ~ Y ~  r   ~ o  ~ v ~  Z   ~  H ~  ~     ~   ~   ~   ~    ~   ~ R  ~ N   ~   ~ "  ~ w j-                         PH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,,, , ,  $   &  '  (  ~ V1 ~     ~ rq  ~ V# ~  z&   ~  (  ~   ~  F   ~   ~   ~    ~    ~   ~ "  ~ w 2                        PH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} ,,,,,, , , , , ,,,,,,,,,,,   %    &  '  (( ) ~ Ʀ   *   ~ Ʀ +   ~     ~  , ~ Ʀ  ~   ~ ơ  -(  . ~   ~   ~   / ~   ~   ~   0 ~ >  ~   ~   1 ~ g ~   h   ~  2( 3 ~ v^ ~  6|   ~ B 4 ~ . ~     ~  5 ~  ~     ~   ~  ~     ~  7 ~ R ~  n   ~ N 8 ~  ~     ~  9 ~       ~  : ~  ~     ~ v                                                      PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,, , , ,   %   &  '   ~  ~  F   ~ bd  ~ V ~  P   ~  H ~   ~     ~ N  ~   ~    ~     ~   ~    ~    ~   ~   ~  j-                         PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,,, , ,  %    &  '  (  ~ Z ~     ~ v  ~ bh ~     ~ b (  ~ ` ~  W   ~   ~ =  ~ :'  ~ v   ~   ~   ~  3                       PH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , , , , , ,   % &  '   ^ ~ S ~  r  b ~  ~    j ~ u ~    k ~ .  ~ B         PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !,!,!,!,!,!, !, !, !, !, !,!,!,!,!,   .           ~      ~    H ~      ~ S   H   ffffff@       ~     H  ~        ~     H  ~      @   H @     @   H                                                                             PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} !!,!,!,!,!,!,!, !, !, !, !, !,!,!,!,!,!,!,!,!,!,!,!,!,!,!,~       ~     H ffffff@     ffffff@   H ~ [     ~ [   H ~      ~    H   @        @    H   ffffff@        ffffff@    H  q= ףp@     q= ףp@   H  : H  : H  : H  : H  : H  : H                                                                                                                  PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , @,,,,           R PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  ,,,,,,,        j PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , , , , , , , , , , , , , , , , , , , , , @ ,                        j-         PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @              J   PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @              J   PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @               J   PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U}  , , @               J   PHt0(  t>@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@Ղg@Ղg՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookykCompObjIOle SummaryInformation(DocumentSummaryInformation8h